Johnson & Johnson JNJ · NYSE
$253.96 -0.63% (-$1.60)
Summary
66 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 16 USD is left as net profit.
- It has raised its dividend 23 years in a row.
- Earnings per share grew by 18% a year over the last 3 years.
- It earns 15 USD a year on every 100 USD of invested capital.
What to watch
- You pay 38.0 USD for 1 USD of yearly profit, a lot for its sector.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.0 USD for 1 USD of yearly profit. Over the last five years it was 20.7 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.7% a year over 5 years. Over the last 3 years it grew by 5.6% a year. For the next fiscal year analysts expect revenue to fall by 0.5%. Earnings per share grew by 18% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Research and development 16 USD
- Sales and administration 29 USD
- Taxes and other 9.5 USD
- Net profit 16 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 16 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 2.08%
- Paid out of profit
- 79%
- Raised in a row
- 23 years
You receive $5.28 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 21
- Hold 16
- Sell 3
Today's price within the analysts' price targets
The average target of $284.5 is 12% above today's price. 53% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Innovative Medicine 64%
- MedTech 36%
By region
- UNITED STATES 57%
- Europe 23%
- Asia-Pacific, Africa 15%
- Western Hemisphere, excluding U.S. 5.2%
Innovative Medicine brings in 64% of revenue. MedTech grew fastest, by 7.2% a year.
Segments in detail